Last reviewed · How we verify
NCT07354477: (PENGUIN)
An Exploratory, Pilot, Single-site Study to Evaluate the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Phase 2 trial testing QLS-111 Ophthalmic Solution (0.015%) in Non-proliferative Diabetic Retinopathy (NPDR) in 14 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Qlaris Bio, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 20 February 2026 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- QLS-111 Ophthalmic Solution (0.015%) — full drug profile →
- QLS-111 Ophthalmic Solution (0.075%) — full drug profile →
Conditions studied
- Non-proliferative Diabetic Retinopathy (NPDR) — all drugs for Non-proliferative Diabetic Retinopathy (NPDR) →
- Open-angle Glaucoma (OAG) — all drugs for Open-angle Glaucoma (OAG) →
- Normal Tension Glaucoma (NTG) — all drugs for Normal Tension Glaucoma (NTG) →
Sponsor
Qlaris Bio, Inc. — full company profile →
Who can join
18 and older, any sex, with Non-proliferative Diabetic Retinopathy (NPDR) or Open-angle Glaucoma (OAG). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Change from Baseline in blood flow to the posterior segment of the eye.
Time frame: Days 1 through 22
Ocular imaging will be collected at study visits at baseline, treatment period , and 1 week post-treatment and to evaluate change from baseline in retinal vessel diameter and blood flow.
Sponsor's own description
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07354477
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Qlaris Bio, Inc. trials
Trials by the same sponsor.
- NCT07354516 — Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension · Phase 2, PHASE3 · recruiting
- NCT06030193 — Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) · Phase 2 · completed
- NCT06249152 — Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients · Phase 2 · completed
- NCT06016972 — Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients · Phase 2 · completed
- NCT05495269 — Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevate · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07354477 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qlaris Bio, Inc.
- Last refreshed: 21 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07354477.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing